An Open-label, Single-centre, Randomised, Two-period, Cross-over Study to Assess the Efficacy and Safety of Day and Night Automated Closed-loop Glucose Control for 24 Hours in Adults With Type 1 Diabetes Comparing Faster-acting Insulin Aspart With Insulin Aspart
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 19 Aug 2022 Status changed from recruiting to completed.
- 06 Dec 2021 Planned End Date changed from 1 Feb 2022 to 1 Jul 2022.
- 06 Dec 2021 Planned primary completion date changed from 1 Nov 2021 to 1 Jul 2022.